BiotechTube

OSE2101 + Docetaxel

Phase 3Recruiting
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Patients With Non-Small Cell Lung Cancer

Conditions

Patients With Non-Small Cell Lung Cancer

Trial Timeline

Dec 3, 2024 → Dec 15, 2028

NCT ID
NCT06472245

About OSE2101 + Docetaxel

OSE2101 + Docetaxel is a phase 3 stage product being developed by OSE Immunotherapeutics for Patients With Non-Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06472245. Target conditions include Patients With Non-Small Cell Lung Cancer.

What happened to similar drugs?

18 of 20 similar drugs in Patients With Non-Small Cell Lung Cancer were approved

Approved (18) Terminated (1) Active (2)
✅ATG-FAstellas PharmaApproved
✅Clopidogrel + TicagrelorAstraZenecaApproved
✅OlaparibAstraZenecaApproved
✅BenralizumabAstraZenecaApproved
✅GefitinibAstraZenecaApproved
✅Imipenem + ImipenemMerckApproved
✅Cyclosporine - cyclosporine microemulsionNovartisApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06472245Phase 3Recruiting

Competing Products

20 competing products in Patients With Non-Small Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
R744 + R744Chugai PharmaceuticalPhase 3
40
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
40
R744 + Epoetin betaChugai PharmaceuticalPhase 3
40
R744 + R744Chugai PharmaceuticalPhase 3
40
R744 + R744Chugai PharmaceuticalPhase 3
40
R744Chugai PharmaceuticalPhase 3
40
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
32
FK949EAstellas PharmaPhase 1
29
roxadustatAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
ASP8825Astellas PharmaPhase 1
29
ASP015KAstellas PharmaPhase 1
29
ASP7991Astellas PharmaPhase 1
29
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
40
ATG-FAstellas PharmaApproved
43
CelecoxibAstellas PharmaPre-clinical
26
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
FK949EAstellas PharmaPhase 1
29